Hilde Ween
Overview
Explore the profile of Hilde Ween including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
301
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gronlien J, Ween H, Thorin-Hagene K, Cassar S, Li J, Briggs C, et al.
Eur J Pharmacol
. 2010 Sep;
647(1-3):37-47.
PMID: 20816816
Genistein and 5-hydroxyindole (5-HI) potentiate the α7 nicotinic acetylcholine receptor current by primarily increasing peak amplitude, a property of type I α7 positive allosteric modulation. In this study, the effects...
2.
Ween H, Thorin-Hagene K, Andersen E, Gronlien J, Lee C, Gopalakrishnan M, et al.
Neurochem Int
. 2010 Jun;
57(3):269-77.
PMID: 20558224
Alpha3-containing (alpha 3*) and alpha 7 nicotinic acetylcholine receptors (nAChRs) are expressed in human IMR-32 neuroblastoma cells and implicated in Ca(2+) signaling. In this study, we investigated the intracellular Ca(2+)...
3.
Malysz J, Anderson D, Gronlien J, Ji J, Bunnelle W, Hakerud M, et al.
J Pharmacol Exp Ther
. 2010 May;
334(3):863-74.
PMID: 20504915
Enhancement of alpha7 nicotinic acetylcholine receptor (nAChR) activity is considered a therapeutic approach for ameliorating cognitive deficits present in Alzheimer's disease and schizophrenia. In this study, we describe the in...
4.
Briggs C, Gronlien J, Curzon P, Timmermann D, Ween H, Thorin-Hagene K, et al.
Br J Pharmacol
. 2009 Oct;
158(6):1486-94.
PMID: 19845675
Background And Purpose: Several agonists of the alpha7 nicotinic acetylcholine receptor (nAChR) have been developed for treatment of cognitive deficits. However, agonist efficacy in vivo is difficult to reconcile with...
5.
Malysz J, Gronlien J, Timmermann D, Hakerud M, Thorin-Hagene K, Ween H, et al.
Assay Drug Dev Technol
. 2009 Aug;
7(4):374-90.
PMID: 19689206
Neuronal acetylcholine receptors (nAChRs) of the alpha7 subtype are ligand-gated ion channels that are widely distributed throughout the central nervous system and considered as attractive targets for the treatment of...
6.
Bunnelle W, Tietje K, Frost J, Peters D, Ji J, Li T, et al.
J Med Chem
. 2009 Jun;
52(14):4126-41.
PMID: 19552432
A series of 5-(pyridine-3-yl)octahydropyrrolo[3,4-c]pyrroles have been prepared that exhibit high affinity to alpha4beta2 and/or alpha7 nicotinic acetylcholine receptors (nAChRs). Simple substitution patterns have been identified that allow construction of ligands...
7.
Faghih R, Gopalakrishnan S, Gronlien J, Malysz J, Briggs C, Wetterstrand C, et al.
J Med Chem
. 2009 May;
52(10):3377-84.
PMID: 19419141
The discovery of a series of pyrrole-sulfonamides as positive allosteric modulators (PAM) of alpha7 nAChRs is described. Optimization of this series led to the identification of 19 (A-867744), a novel...
8.
Malysz J, Gronlien J, Anderson D, Hakerud M, Thorin-Hagene K, Ween H, et al.
J Pharmacol Exp Ther
. 2009 Apr;
330(1):257-67.
PMID: 19389923
Targeting alpha7 neuronal acetylcholine receptors (nAChRs) with selective agonists and positive allosteric modulators (PAMs) is considered a therapeutic approach for managing cognitive deficits in schizophrenia and Alzheimer's disease. In this...
9.
Tietje K, Anderson D, Bitner R, Blomme E, Brackemeyer P, Briggs C, et al.
CNS Neurosci Ther
. 2008 May;
14(1):65-82.
PMID: 18482100
Among the diverse sets of nicotinic acetylcholine receptors (nAChRs), the alpha7 subtype is highly expressed in the hippocampus and cortex and is thought to play important roles in a variety...
10.
Gronlien J, Hakerud M, Ween H, Thorin-Hagene K, Briggs C, Gopalakrishnan M, et al.
Mol Pharmacol
. 2007 Jun;
72(3):715-24.
PMID: 17565004
Selective modulation of alpha7 nicotinic acetylcholine receptors (nAChRs) is thought to regulate processes impaired in schizophrenia, Alzheimer's disease, and other dementias. One approach to target alpha7 nAChRs is by positive...